Azenta, Inc. Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended March 31, 2022; financial statements are unaudited. The filing reflects Azenta’s post-divestiture life sciences operations, with the semiconductor automation business presented as discontinued operations.
Business Context
Azenta provides life sciences sample management, automated storage, genomic services, sample repository solutions, consumables, informatics, and related laboratory services. The company completed the sale of its semiconductor automation business to Thomas H. Lee Partners on February 1, 2022, for approximately $2.9 billion in cash, subject to customary adjustments. Expected net proceeds were approximately $2.5 billion after taxes and transaction costs.
Following the transaction, the company operates through two reportable segments: Life Sciences Products and Life Sciences Services. Azenta changed its name from Brooks Automation, Inc. and began trading under the ticker AZTA on December 1, 2021.
Financial Highlights
| Metric | Three months ended March 31 | Six months ended March 31 |
|---|---|---|
| Revenue | $145.5 million, up 12% | $285.2 million, up 15% |
| Gross profit | $70.8 million | $137.9 million |
| Gross margin | 48.7%, versus 44.7% | 48.3%, versus 46.5% |
| Operating loss | $4.7 million, versus $9.3 million | $5.0 million, versus $9.0 million |
| Income from continuing operations | Loss of $1.8 million | Income of $1.0 million |
| Net income | $2.120 billion | $2.163 billion |
| Diluted earnings per share | $28.28 | $28.79 |
Net income and earnings per share were dominated by the approximately $2.1 billion after-tax gain from the semiconductor automation divestiture. Continuing operations remained near break-even or loss-making.
Revenue by Segment
| Segment | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Life Sciences Products | $53.6 million | $52.4 million | $103.5 million | $97.9 million |
| Life Sciences Services | $91.9 million | $77.2 million | $181.7 million | $149.8 million |
Life Sciences Services drove growth, increasing 19% in the quarter and 21% for the six-month period. Life Sciences Products increased 2% in the quarter and 6% year to date. Management attributed services growth to sample repository and genomic services demand.
Cash Flow, Liquidity, Debt, and Balance Sheet
- Cash, cash equivalents, restricted cash, and marketable securities totaled approximately $3.0 billion at March 31, 2022, compared with $244.0 million at September 30, 2021.
- Cash, cash equivalents, and restricted cash were approximately $1.949 billion, compared with $285.3 million at September 30, 2021.
- Marketable securities totaled approximately $1.077 billion, primarily U.S. government, corporate, and municipal securities.
- Operating cash flow was an outflow of $55.7 million for the six months ended March 31, 2022, compared with $77.9 million of inflow in the prior-year period. The current-period outflow reflected transaction fees, working-capital investment, and the noncash divestiture gain reconciliation.
- Investing cash flow was an inflow of $1.808 billion, including $2.927 billion of divestiture proceeds and $1.074 billion of marketable-security purchases.
- Capital expenditures were $44.3 million; the company also spent $4.0 million on technology intangible assets.
- The $49.7 million term loan was repaid on February 1, 2022, and the revolving credit facility was terminated. The company reported no outstanding debt at March 31, 2022.
- Non-cancellable commitments totaled $97.0 million, including $76.7 million of inventory purchase orders, $16.7 million of information-technology commitments, and $3.6 million related to the China facility.
- Accrued income taxes were $430.7 million at March 31, 2022, primarily reflecting taxes associated with the divestiture.
Material Changes Versus the Prior Comparable Period
- Continuing-operations revenue increased 12% in the quarter and 15% for the six-month period.
- Gross margin expanded by 4.0 percentage points in the quarter and 1.8 percentage points year to date, aided by cost reductions, product mix, and comparison against prior-year tariff accruals.
- Operating expenses increased $8.3 million in the quarter and $18.7 million year to date, principally from higher research and development and selling, general and administrative expenses.
- Segment adjusted operating income declined to $10.1 million from $12.9 million in the quarter and to $22.4 million from $24.0 million year to date. Segment adjusted operating margin declined to 7% from 10% in the quarter and to 8% from 10% year to date.
- Operating results benefited from a $0.5 million tariff-accrual reduction in the current quarter, compared with a $5.5 million tariff charge in the prior-year quarter.
- Interest income increased materially because of the cash received from the divestiture, while foreign-currency losses increased.
- The company incurred $0.6 million of debt-extinguishment losses and paid $9.4 million of acquisition-related contingent consideration.
Outlook, Commentary, Risks, and Unusual Items
The filing does not provide a clear numerical revenue, margin, or earnings forecast. Management stated that it expects adequate resources to meet working-capital, financing, debt-service, and capital-expenditure requirements for at least the next twelve months.
- Management expects approximately $2.5 billion of net divestiture proceeds after taxes and other costs.
- COVID-19 had an estimated positive net revenue impact of approximately $10 million in the quarter and $20 million in the six-month period, although the filing notes uncertainty from future variants, restrictions, supply-chain constraints, and changes in customer demand.
- Azenta experienced a two-week facility closure in Suzhou, China during the subsequent quarter due to local COVID-19 mandates; management did not believe it had a material impact on reported results.
- Key risks include supply-chain disruption, labor and wage inflation, customer demand fluctuations, foreign-exchange movements, tariffs and export controls, cybersecurity, regulatory compliance, and dependence on skilled personnel.
- The company had a $7.4 million tariff accrual at March 31, 2022. It subsequently paid $5.9 million to customs authorities for prior periods, subject to further customs review.
- The company is subject to ordinary-course legal proceedings and indemnification claims related to a prior divestiture. Management does not currently expect a material adverse effect, but outcomes remain uncertain.
- The filing states that disclosure controls and procedures were effective and that no material changes occurred in internal control over financial reporting.
Investor Verification Priorities
- Verify the final net cash proceeds, tax payments, working-capital adjustments, and any remaining obligations from the semiconductor automation sale.
- Separate recurring life sciences operating performance from the one-time divestiture gain when assessing earnings and valuation.
- Monitor whether Life Sciences Services growth can offset lower segment margins, higher labor costs, and elevated operating expenses.
- Assess cash deployment plans for the approximately $3.0 billion liquidity position, including investments, acquisitions, dividends, and potential share repurchases.
- Review the ultimate resolution of the tariff matter, customs review, tax liabilities, and prior-divestiture indemnification claims.
- Evaluate the effects of COVID-19 restrictions, supply-chain constraints, foreign-exchange volatility, and the Suzhou facility disruption on subsequent periods.